Folger Nolan Fleming Douglas Capital Management Inc. Has $15.46 Million Holdings in Johnson & Johnson $JNJ

Folger Nolan Fleming Douglas Capital Management Inc. cut its holdings in Johnson & Johnson (NYSE:JNJ) by 1.1% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 101,202 shares of the company’s stock after selling 1,135 shares during the quarter. Johnson & Johnson makes up 1.7% of Folger Nolan Fleming Douglas Capital Management Inc.’s holdings, making the stock its 14th biggest holding. Folger Nolan Fleming Douglas Capital Management Inc.’s holdings in Johnson & Johnson were worth $15,459,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. GFG Capital LLC bought a new position in Johnson & Johnson in the second quarter valued at about $35,000. Highline Wealth Partners LLC raised its position in Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after purchasing an additional 86 shares during the last quarter. Stone House Investment Management LLC bought a new position in Johnson & Johnson in the first quarter valued at about $47,000. 1248 Management LLC bought a new position in Johnson & Johnson in the first quarter valued at about $48,000. Finally, von Borstel & Associates Inc. bought a new position in shares of Johnson & Johnson during the first quarter worth about $49,000. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Trading Up 0.1%

NYSE JNJ opened at $190.88 on Tuesday. The business has a 50 day simple moving average of $178.88 and a 200 day simple moving average of $163.97. Johnson & Johnson has a one year low of $140.68 and a one year high of $192.10. The stock has a market capitalization of $459.71 billion, a P/E ratio of 20.42, a P/E/G ratio of 2.40 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm had revenue of $24.02 billion during the quarter. Research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio (DPR) is 55.61%.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on JNJ. Barclays raised their price objective on Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 17th. Sanford C. Bernstein raised their price objective on Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a research report on Monday, October 6th. Wall Street Zen upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. Weiss Ratings upgraded Johnson & Johnson from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, October 8th. Finally, UBS Group set a $198.00 price objective on Johnson & Johnson in a research report on Friday, October 3rd. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $192.94.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.